{"id":684023,"date":"2024-01-09T18:58:01","date_gmt":"2024-01-09T18:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=684023"},"modified":"2024-01-09T18:58:01","modified_gmt":"2024-01-09T18:58:01","slug":"crispr-therapies-pipeline-report-fda-ema-and-pmda-approvals-treatments-clinical-trials-phases-and-companies-by-delveinsight-intellia-therapeutics-crispr-therapeutics-astrazeneca-novartis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/crispr-therapies-pipeline-report-fda-ema-and-pmda-approvals-treatments-clinical-trials-phases-and-companies-by-delveinsight-intellia-therapeutics-crispr-therapeutics-astrazeneca-novartis_684023.html","title":{"rendered":"CRISPR Therapies Pipeline Report: FDA, EMA, and PMDA Approvals, Treatments, Clinical Trials, Phases, and Companies by DelveInsight | Intellia Therapeutics, CRISPR Therapeutics, AstraZeneca, Novartis"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1704776273.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"CRISPR Therapies Pipeline Report: FDA, EMA, and PMDA Approvals, Treatments, Clinical Trials, Phases, and Companies by DelveInsight | Intellia Therapeutics, CRISPR Therapeutics, AstraZeneca, Novartis\" src=\"https:\/\/www.abnewswire.com\/uploads\/1704776273.jpeg\" alt=\"CRISPR Therapies Pipeline Report: FDA, EMA, and PMDA Approvals, Treatments, Clinical Trials, Phases, and Companies by DelveInsight | Intellia Therapeutics, CRISPR Therapeutics, AstraZeneca, Novartis\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>CRISPR Therapies Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>(New York, USA)<\/strong> &ldquo;<strong>CRISPR therapies Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR therapies Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The CRISPR therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about the CRISPR therapies pipeline report, click here: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/crispr-therapies-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">CRISPR therapies Pipeline Insight<\/a> <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of the CRISPR therapies pipeline report are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>CRISPR therapies pipeline constitutes 25+ key companies continuously working towards developing 30+ CRISPR therapies treatment therapies, analyses DelveInsight<\/li>\n<li>Leading CRISPR therapies companies working in the market are Intellia Therapeutics, CRISPR therapeutics, Vertex Pharmaceuticals, Repare Therapeutics, Beam therapeutics, Caribou Biosciences, Emendo Biotherapeutics, Defence Therapeutics, Sarepta therapeutics, Editas Medicine, Locus Biosciences, Excision BioTherapeutics, AstraZeneca, Novartis, ASC therapeutics, Casebia therapeutics, Spotlight Therapeutics, KSQ Therapeutics, MEDIC Life Sciences, Scribe therapeutics, Arbor Biotechnologies, Sangamo therapeutics, Graphite Bio, Nuntius Therapeutics and many others.<\/li>\n<li>Promising CRISPR therapies include CTX001, EDIT-101, CRISPR-based ex vivo cell therapy exagamglogene autotemcel (exa-cel) and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>CRISPR Overview:<\/strong><\/p>\n<p style=\"text-align: justify;\">CRISPRs, short for &#8220;clusters of regularly interspaced short palindromic repeats,&#8221; are specialized segments of DNA distinguished by two primary features: repeated sequences of nucleotides, the building blocks of DNA, dispersed throughout the CRISPR region, and interspersed bits of DNA called spacers. These spacers within CRISPRs function in bacterial immunity regulation by retaining memories of previously encountered viruses. When bacteria encounter viruses, they incorporate snippets of viral DNA into their CRISPR arrays, creating a memory bank that aids in identifying and defending against future viral attacks. The revolutionary CRISPR\/Cas9 gene-editing tool, stemming from this bacterial defense mechanism, has transformed biomedical research. Its potential in clinical trials signals a new era in CRISPR gene therapy, offering promising avenues for groundbreaking medical advancements.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know in detail about the CRISPR therapies clinical trials and advancements @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crispr-therapies-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/crispr-therapies-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s CRISPR therapies Report covers around 30+ CRISPR products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage CRISPR products (Phase III)<\/li>\n<li>Mid-stage CRISPR products (Phase II)<\/li>\n<li>Early-stage CRISPR product (Phase I)<\/li>\n<li>CRISPR Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>CRISPR Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging CRISPR therapies Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>CTX001: CRISPR Therapeutics<\/li>\n<li>EDIT-101: Editas Medicine<\/li>\n<li>And Many Others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further CRISPR therapies product details are provided in the report. Download the CRISPR report to learn more about the emerging CRISPR therapies at: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crispr-therapies-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/crispr-therapies-pipeline-insight<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>CRISPR therapies Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The CRISPR therapies report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the <strong>treatment of CRISPR therapies<\/strong> with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the <strong>CRISPR therapies Treatment<\/strong>.<\/li>\n<li><strong>CRISPR therapies key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li><strong>CRISPR therapies Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the <strong>CRISPR therapies market.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report for CRISPR therapies pipeline assessment- <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crispr-therapies-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/crispr-therapies-pipeline-insight<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key companies in the CRISPR therapies Therapeutics Market:<\/strong><\/p>\n<p style=\"text-align: justify;\">Some of the CRISPR companies working in the market are Intellia Therapeutics, CRISPR therapeutics, Repare Therapeutics, Beam therapeutics, Caribou Biosciences, Emendo Biotherapeutics, Defence Therapeutics, Sarepta therapeutics, Editas Medicine, Locus Biosciences, Excision BioTherapeutics, AstraZeneca, Novartis, ASC therapeutics, Casebia therapeutics, Spotlight Therapeutics,KSQ Therapeutics, MEDIC Life Sciences, Scribe therapeutics, Arbor Biotechnologies, Sangamo therapeutics,Graphite Bio, Nuntius Therapeutics.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report to know more about the CRISPR therapies and drugs by clicking here @ CRISPR therapies drugs and medication: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crispr-therapies-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/crispr-therapies-pipeline-insight<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. CRISPR therapies Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. CRISPR therapies &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. CRISPR Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6.&nbsp; CRISPR therapies Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7.&nbsp; CRISPR therapies Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8.&nbsp; CRISPR therapies Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9.&nbsp;CRISPR Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive CRISPR Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant CRISPR Products<\/p>\n<p style=\"text-align: justify;\">12.&nbsp; CRISPR therapies Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13.&nbsp; CRISPR therapies Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Key Companies in the CRISPR therapies Market<\/p>\n<p style=\"text-align: justify;\">15. Key Products in the CRISPR therapies Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. CRISPR therapies Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18.&nbsp;CRISPR therapies Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. CRISPR therapies Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=crispr-therapies-pipeline-report-fda-ema-and-pmda-approvals-treatments-clinical-trials-phases-and-companies-by-delveinsight-intellia-therapeutics-crispr-therapeutics-astrazeneca-novartis\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +91-9650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=crispr-therapies-pipeline-report-fda-ema-and-pmda-approvals-treatments-clinical-trials-phases-and-companies-by-delveinsight-intellia-therapeutics-crispr-therapeutics-astrazeneca-novartis\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CRISPR Therapies Pipeline (New York, USA) &ldquo;CRISPR therapies Pipeline Insight, 2023&rdquo; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR therapies Market.&nbsp; The CRISPR therapies Pipeline report embraces in-depth commercial and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/crispr-therapies-pipeline-report-fda-ema-and-pmda-approvals-treatments-clinical-trials-phases-and-companies-by-delveinsight-intellia-therapeutics-crispr-therapeutics-astrazeneca-novartis_684023.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-684023","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/684023","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=684023"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/684023\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=684023"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=684023"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=684023"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}